Biogen

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Biogen and other ETFs, options, and stocks.

About BIIB

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. It offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of multiple sclerosis, SPINRAZA for the treatment of spinal muscular atrophy, and FUMADERM for the treatment of severe plaque psoriasis.

CEO

Christopher A. Viehbacher

CEOChristopher A. Viehbacher

Employees

9,610

Employees9,610

Headquarters

Cambridge, Massachusetts

HeadquartersCambridge, Massachusetts

Founded

1978

Founded1978

Employees

9,610

Employees9,610

BIIB Key Statistics

Market cap

42.02B

Market cap42.02B

Price-Earnings ratio

14.89

Price-Earnings ratio14.89

Dividend yield

—

Dividend yield—

Average volume

1.02M

Average volume1.02M

High today

$293.01

High today$293.01

Low today

$289.67

Low today$289.67

Open price

$292.34

Open price$292.34

Volume

557.32K

Volume557.32K

52 Week high

$311.88

52 Week high$311.88

52 Week low

$187.16

52 Week low$187.16

BIIB News

Reuters 2h

UPDATE 1-EU regulator accepts for review Alzheimer's treatment from Eisai-Biogen

(Adds background) Jan 26 (Reuters) - Japanese drugmaker Eisai Co Ltd and Biogen Inc said on Thursday the European Medicines Agency (EMA) had accepted a marketi...

Yahoo Finance 3h

Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer's Disease Accepted by European ... - Yahoo Finance

Biogen Inc. TOKYO and CAMBRIDGE, Mass., Jan. 26, 2023 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nas...

Reuters 6d

Eli Lilly Alzheimer's drug setback extends rival Biogen's lead - Reuters

Jan 20 (Reuters) - The U.S. health regulator's rejection of accelerated approval for Eli Lilly and Co's Alzheimer's disease drug extends the marke...

Analyst ratings

64%

of 33 ratings

Buy

63.6%

Hold

36.4%

Sell

BIIB Earnings

$0.00

$1.89

$3.79

$5.68

Q2 FY21

Q3 FY21

Q4 FY21

Q1 FY22

Q2 FY22

Q3 FY22

Q4 FY22

Estimated

$3.48 per share

Estimated$3.48 per share

Actual

Available Feb 15, Pre-Market

ActualAvailable Feb 15, Pre-Market

More BIIB News

Investor's Business Daily 6d

In A Stunner, Eli Lilly Stock Falls After FDA Delivers A Blow To Its Alzheimer's Drug

Eli Lilly (LLY) stock dipped Friday after the Food and Drug Administration unexpectedly rejected its request for an accelerated approval of its Alzheimer's trea...